132 related articles for article (PubMed ID: 1978329)
21. Structural effects of substitutions on the p21 proteins.
Pincus MR; Brandt-Rauf PW
Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3596-3600. PubMed ID: 3923480
[TBL] [Abstract][Full Text] [Related]
22. Prediction of the three-dimensional structure of the transforming region of the EJ/T24 human bladder oncogene product and its normal cellular homologue.
Pincus MR; van Renswoude J; Harford JB; Chang EH; Carty RP; Klausner RD
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5253-7. PubMed ID: 6577419
[TBL] [Abstract][Full Text] [Related]
23. Alterations of the c-erbB2 gene in human breast cancer.
Zoll B; Kynast B; Corell B; Marx D; Fischer G; Schauer A
J Cancer Res Clin Oncol; 1992; 118(6):468-73. PubMed ID: 1352298
[TBL] [Abstract][Full Text] [Related]
24. Conformational effects of substituting amino acids for glutamine-61 on the central transforming region of the P21 proteins.
Pincus MR; Brandt-Rauf PW; Carty RP; Lubowsky J; Avitable M; Gibson KD; Scheraga HA
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8375-9. PubMed ID: 3120190
[TBL] [Abstract][Full Text] [Related]
25. Three dimensional structure of the transmembrane region of the proto-oncogenic and oncogenic forms of the neu protein.
Gullick WJ; Bottomley AC; Lofts FJ; Doak DG; Mulvey D; Newman R; Crumpton MJ; Sternberg MJ; Campbell ID
EMBO J; 1992 Jan; 11(1):43-8. PubMed ID: 1346763
[TBL] [Abstract][Full Text] [Related]
26. Stage- and tissue-specific expression of the neu oncogene in rat development.
Kokai Y; Cohen JA; Drebin JA; Greene MI
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8498-501. PubMed ID: 3317411
[TBL] [Abstract][Full Text] [Related]
27. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
Yu D; Shi D; Scanlon M; Hung MC
Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Zhai YF; Beittenmiller H; Wang B; Gould MN; Oakley C; Esselman WJ; Welsch CW
Cancer Res; 1993 May; 53(10 Suppl):2272-8. PubMed ID: 8097963
[TBL] [Abstract][Full Text] [Related]
29. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
[TBL] [Abstract][Full Text] [Related]
30. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
Mikami Y; Davis JG; Dobashi K; Dougall WC; Myers JN; Brown VI; Greene MI
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7335-9. PubMed ID: 1354355
[TBL] [Abstract][Full Text] [Related]
31. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.
Dougall WC; Qian X; Greene MI
J Cell Biochem; 1993 Sep; 53(1):61-73. PubMed ID: 7901229
[TBL] [Abstract][Full Text] [Related]
32. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
33. Analysis of structure and activation of some receptor-type tyrosine kinase oncogenes.
Shibuya M; Matsushime H; Yamazaki H; Wang LH; Fukui Y; Ueyama Y; Tamaoki N
Princess Takamatsu Symp; 1986; 17():195-202. PubMed ID: 3455414
[TBL] [Abstract][Full Text] [Related]
34. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.
Shu HK; Pelley RJ; Kung HJ
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9103-7. PubMed ID: 1979168
[TBL] [Abstract][Full Text] [Related]
35. Activated conformations of the ras-gene-encoded p21 protein. 1. An energy-refined structure for the normal p21 protein complexed with GDP.
Dykes DC; Brandt-Rauf P; Luster SM; Chung D; Friedman FK; Pincus MR
J Biomol Struct Dyn; 1992 Jun; 9(6):1025-44. PubMed ID: 1637501
[TBL] [Abstract][Full Text] [Related]
36. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
37. Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations.
Sajot N; Genest M
J Biomol Struct Dyn; 2001 Aug; 19(1):15-31. PubMed ID: 11565846
[TBL] [Abstract][Full Text] [Related]
38. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
Burke CL; Lemmon MA; Coren BA; Engelman DM; Stern DF
Oncogene; 1997 Feb; 14(6):687-96. PubMed ID: 9038376
[TBL] [Abstract][Full Text] [Related]
39. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.
Bargmann CI; Weinberg RA
EMBO J; 1988 Jul; 7(7):2043-52. PubMed ID: 2901345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
